United States Patent 9,447,071: Scope and Claims for Crystalline Ansovates of “Compound 1”
United States Patent 9,447,071 is directed to crystalline ansolvates of “Compound 1” defined by an X-ray powder diffraction (XRPD) fingerprint using Cu Kα radiation. Claim scope is anchored to specific diffraction peaks at 13.37°, 14.37°, 19.95°, and 23.92° (each ±0.2° 2θ), with layered dependent limitations requiring increasing peak counts and strict impurity/mixture ceilings for undesired solid forms (e.g., crystalline Form I, crystalline “Material N,” and amorphous forms). The estate extends beyond the ansolvate solid state to compositions and pharmaceutical compositions containing the defined ansolvate, including excipient-containing formulations.
Core infringement hook: any product (solid, intermediate, or formulated drug substance/drug product) that contains a crystalline ansolvate meeting the asserted XRPD peak criteria, with additional constraints where applicable (purity ceilings; substantially solvated-polymorph exclusion in some claims).
What does US Patent 9,447,071 protect: crystalline ansolvates defined by XRPD peaks?
Claim-independent concept: “crystalline ansolvate of Compound 1” characterized by XRPD peak presence/absence.
What specific XRPD peaks define the invention?
Across the independent claim set (and their dependent variants), the diffraction peaks are fixed as:
- 13.37° 2θ ±0.2°
- 14.37° 2θ ±0.2°
- 19.95° 2θ ±0.2°
- 23.92° 2θ ±0.2°
(all with Cu Kα radiation)
The claims use two types of XRPD limitations:
- “At least one” peak is present (broadest XRPD-defined tier).
- Exact peak set (narrowest tier): “peaks of 13.37°, 14.37°, 19.95° and 23.92°” (effectively requiring all four peaks within tolerance).
How do the “at least one / at least two / at least three / all four peaks” tiers change scope?
- Claim 1: at least one of the four peaks (broad scope; more design-around pressure because many solids may share one coincident peak).
- Claim 2: at least two peaks.
- Claim 3: at least three peaks.
- Claim 4: all four peaks present within tolerance (most restrictive XRPD requirement).
Practical read-through: the estate narrows as you move from Claim 1 → Claim 4, because the probability that an unclaimed solid form shares ≥3 or all 4 peaks within the stated window decreases materially.
What does Claim 5 add: “substantially similar to FIG. 5”?
Claim 5 adds a comparative similarity standard:
- crystalline ansolvate characterized by an XRPD pattern substantially similar to FIG. 5.
This expands coverage beyond the discrete-peak approach by importing a pattern-recognition criterion tied to a reference figure. In litigation, this can allow an argument that a solid with slightly different peak intensities and/or additional peaks is still infringing if its overall pattern matches the figure closely, depending on how “substantially similar” is construed.
How broad is the protection against mixtures of polymorphs and amorphous forms?
The patent adds multiple dependent claims that cap the presence of undesired solid forms in the crystalline ansolvate-containing material. These are not merely identification limitations; they are quantitative composition constraints that can materially shift noninfringement risk to the manufacturing process and quality control.
What impurity ceilings are claimed?
For compositions comprising the ansolvate (and for pharmaceutical compositions containing it), the claims repeatedly use thresholds for the relative amount of other forms:
- less than 25 mole % of crystalline Form I
- less than 25 mole % of crystalline Material N
- less than 25 mole % of amorphous forms
- less than 10 mole % of crystalline Form I
- less than 10 mole % of crystalline Material N
- less than 10 mole % of amorphous forms
- less than 5 mole % of crystalline Form I
- less than 5 mole % of crystalline Material N
- less than 5 mole % of amorphous forms
These appear as Claim 10 and later variants for the “composition” branch, with mirror coverage in the “pharmaceutical composition” branch (Claims 16–33).
What “substantially free of a solvated polymorph” means in scope terms?
Claim 11 (and similarly Claim 17) states the crystalline ansolvate composition is:
- substantially free of a solvated polymorph of Compound 1
This is a qualitative constraint. It functions as an additional gate that reduces the chance that a competitor could “mix in” other solvated forms while still meeting XRPD peak criteria for the ansolvate.
What is the practical scope impact of adding “less than X mole %” constraints?
- If a generic/sponsor produces a solid mixture where the ansolvate meets the XRPD fingerprint but coexists at more than the claimed mole-% levels of Form I, Material N, or amorphous forms, it may avoid dependent claims (even if it still risks independent XRPD-peak claims, depending on which claims are asserted).
- If a product is highly purified and engineered to retain the ansolvate with low impurities, it moves toward the dependent claim coverage.
What formulations are protected: compositions, excipient-containing pharmaceutical compositions, and drug substance?
The claims include two key downstream tiers:
- Compositions comprising the ansolvate (Claims 6–11 and dependent impurity/mixture limitations).
- Pharmaceutical compositions with excipients (Claims 12–17 and dependent impurity/mixture limitations).
Does the patent require a specific excipient or dosage form?
The provided claims do not specify excipient identity or dosage form type beyond “pharmaceutically acceptable excipient.” That means formulation scope is broad on excipient selection, but still anchored to the XRPD-defined ansolvate and the dependent impurity ceilings.
How do the “composition” claims differ from “pharmaceutical composition” claims?
They track closely:
- “composition” claims focus on the solid-state material meeting XRPD and mixture rules.
- “pharmaceutical composition” adds inclusion of excipients while retaining identical XRPD and impurity caps.
From an infringement strategy standpoint, the presence of an excipient layer does not create a safe harbor if the XRPD and composition constraints are met.
Which claims are the broadest and narrowest in infringement coverage?
Broadest XRPD definition
- Claim 1: at least one of the four XRPD peaks (13.37°, 14.37°, 19.95°, 23.92°).
This is the highest-risk category for design-around because requiring only a single peak can be met accidentally or via imperfect matching even among different solids.
Narrowest XRPD definition
- Claim 4: XRPD peaks of all four specified angles (each ±0.2°).
- Claim 5: substantially similar to FIG. 5.
In practical terms, Claim 4 is mechanically narrow; Claim 5 is narrow but could be argued more flexibly based on pattern similarity.
Broadest mixture constraints
- dependent claims with <25 mole % impurity ceilings are broader than <10 and <5, while still providing quantitative limits.
What would a competitor need to avoid to steer clear of the estate?
Using the claim logic provided, a design-around must address two independent axes:
-
XRPD fingerprint avoidance
- Avoid having the required number of peaks within the ±0.2° windows.
- Especially problematic for Claim 1 if a product retains at least one of those peaks.
- More achievable if the product solid form does not match the complete four-peak set of Claim 4 and fails the ≥3 peak tiers.
-
Mixture/purity avoidance (for dependent-claim protection)
- If the product solid contains more than the claimed mole-% of Form I, Material N, or amorphous forms, it can reduce exposure to the dependent claim set.
- However, independent XRPD claims (Claims 1, 6, 12) can still be asserted without the quantitative caps, depending on which claims are pursued.
How strong is the patent estate for crystalline ansolvate products given the claim structure?
Strength drivers in Claim drafting
- The estate uses objective analytical metrics (XRPD peak angles, tolerance, Cu Kα).
- It defines multiple tiers (at least 1, 2, 3, or all 4 peaks) so that partial matching solids still may fall within at least the broadest independent claim.
- It includes quantitative impurity constraints (<25, <10, <5 mole %) for multiple undesired forms, which supports enforceability using standard solid-state characterization.
Key enforceability bottlenecks introduced by the claims themselves
- XRPD peak matching depends on sample preparation, instrument settings, and crystallinity state. The claims narrow tolerance by using ±0.2° 2θ windows, which favors reproducible measurement but can still be contested analytically.
- “Substantially similar to FIG. 5” (Claim 5) introduces interpretive variability tied to figure depiction and how similarity is measured.
What patent landscape conclusions follow from US 9,447,071’s claim scope alone?
Based solely on the claim text supplied, US 9,447,071 should be treated as a solid-form enforcement patent centered on:
- XRPD-identified crystalline ansolvate,
- explicit peak-angle windows,
- and mixture control versus Form I, Material N, and amorphous forms,
across both drug substance-like compositions and excipient-containing pharmaceutical compositions.
This is the kind of patent that can be relevant to:
- initial launch of an ansolvate form,
- lifecycle management if the ansolvate replaces earlier solid forms,
- and potential challenges where a generic attempts to use a different polymorph or amorphous/mixture strategy.
However, without the patent’s specification, priority dates, and family data, a full US-only landscape view (other patents in the same family, related continuations, coverage overlaps with other solid-form patents, and any other MoA/method-of-use estates) cannot be built from the claims alone.
Key Takeaways
- US 9,447,071 claims crystalline ansolvates of “Compound 1” defined by XRPD Cu Kα peaks at 13.37°, 14.37°, 19.95°, 23.92° (±0.2° 2θ).
- Independent claim tiering runs from at least one peak (broad) to all four peaks (narrow), plus an XRPD pattern similarity reference to FIG. 5.
- The estate extends to compositions and pharmaceutical compositions containing the ansolvate with excipients.
- Dependent claims add quantitative purity limits against crystalline Form I, crystalline Material N, and amorphous forms at <25, <10, and <5 mole %.
- The primary infringement risk is controlled by whether the accused product hits the XRPD peak count requirements and, for dependent claims, whether it stays below the impurity/mixture mole-% ceilings.
FAQs
1) What is the minimum XRPD requirement to fall under the broadest claim tier?
At least one of the four Cu Kα XRPD peaks: 13.37°, 14.37°, 19.95°, or 23.92° (each ±0.2° 2θ).
2) How do “at least two” and “at least three” peak claims change litigation leverage?
They increase specificity by requiring concurrence of multiple fingerprint peaks within the defined tolerances, reducing the chance of incidental overlap with unrelated solid forms.
3) What thresholds exist for Form I, Material N, and amorphous forms?
The dependent claims recite impurity ceilings of <25 mole %, <10 mole %, and <5 mole % for crystalline Form I, crystalline Material N, and amorphous forms (with corresponding coverage in both composition and pharmaceutical composition branches).
4) Can a competitor avoid infringement by using an ansolvate that matches only FIG. 5 but not the peak list?
If the FIG. 5 pattern is argued as “substantially similar” (Claim 5), a product could still be targeted even if a disputed subset of the discrete peak list is not met, depending on claim construction and the proof method used.
5) Does the patent require a specific excipient composition?
No. The pharmaceutical composition claims require pharmaceutically acceptable excipients but do not limit the excipient type in the claim language provided.
